BR0014384A - Compostos para o tratamento da isquémia - Google Patents

Compostos para o tratamento da isquémia

Info

Publication number
BR0014384A
BR0014384A BR0014384-7A BR0014384A BR0014384A BR 0014384 A BR0014384 A BR 0014384A BR 0014384 A BR0014384 A BR 0014384A BR 0014384 A BR0014384 A BR 0014384A
Authority
BR
Brazil
Prior art keywords
ischemia
compounds
agonists
treatment
hypoxia
Prior art date
Application number
BR0014384-7A
Other languages
English (en)
Inventor
Hiroko Masamune
Michael Paul Deninno
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0014384A publication Critical patent/BR0014384A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "COMPOSTOS PARA O TRATAMENTO DA ISQUéMIA". Agonistas de A~ 3~, procedimentos para o emprego de tais agonistas e de composições farmacêuticas que contenham tais agonistas de A~ 3~. Os agonistas de A~ 3~ são úteis na redução de danos em tecidos que resultem de isquémia ou hipoxia.
BR0014384-7A 1999-09-30 2000-09-22 Compostos para o tratamento da isquémia BR0014384A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (1)

Publication Number Publication Date
BR0014384A true BR0014384A (pt) 2002-07-02

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014384-7A BR0014384A (pt) 1999-09-30 2000-09-22 Compostos para o tratamento da isquémia

Country Status (41)

Country Link
EP (1) EP1216257B1 (pt)
JP (1) JP2003510331A (pt)
KR (1) KR100481605B1 (pt)
CN (1) CN1374967A (pt)
AP (1) AP2002002458A0 (pt)
AR (1) AR029887A1 (pt)
AT (1) ATE312117T1 (pt)
AU (1) AU778185B2 (pt)
BG (1) BG106636A (pt)
BR (1) BR0014384A (pt)
CA (1) CA2386079A1 (pt)
CO (1) CO5180581A1 (pt)
CR (1) CR6592A (pt)
CZ (1) CZ20021020A3 (pt)
DE (1) DE60024649D1 (pt)
EA (1) EA005422B1 (pt)
EC (1) ECSP003682A (pt)
EE (1) EE200200172A (pt)
GE (1) GEP20043241B (pt)
GT (1) GT200000161A (pt)
HK (1) HK1049011A1 (pt)
HR (1) HRP20020253A2 (pt)
HU (1) HUP0202807A3 (pt)
IL (1) IL148222A0 (pt)
IS (1) IS6286A (pt)
MA (1) MA26822A1 (pt)
MX (1) MXPA02003308A (pt)
MY (1) MY133996A (pt)
NO (1) NO20021474L (pt)
NZ (1) NZ517177A (pt)
OA (1) OA12021A (pt)
PA (1) PA8503301A1 (pt)
PE (1) PE20010696A1 (pt)
PL (1) PL357371A1 (pt)
SK (1) SK4182002A3 (pt)
TN (1) TNSN00191A1 (pt)
TR (1) TR200200843T2 (pt)
UA (1) UA73525C2 (pt)
WO (1) WO2001023399A1 (pt)
YU (1) YU23102A (pt)
ZA (1) ZA200202461B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
HRP20040385A2 (en) * 2001-11-02 2005-06-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising an adenosine a<sub>1</sub>/a<sub>2</sub> agonist and a sodium hydrogen exchanger inhibitor
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007513082A (ja) * 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.
NZ551077A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1778239B1 (en) * 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
EP1781331A1 (en) * 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
BRPI0515121A (pt) * 2004-08-30 2008-07-08 Janssen Pharmaceutica Nv derivados da n-2 adamantil-2-fenóxi acetamida como inibidores da 11-beta hidroxiesteróide desidrogenase
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (pt) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
DE69428536T2 (de) * 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten

Also Published As

Publication number Publication date
ATE312117T1 (de) 2005-12-15
CZ20021020A3 (cs) 2003-04-16
HUP0202807A2 (hu) 2002-12-28
IS6286A (is) 2002-02-26
TR200200843T2 (tr) 2002-07-22
DE60024649D1 (de) 2006-01-12
EA200200316A1 (ru) 2002-08-29
OA12021A (en) 2006-04-19
TNSN00191A1 (fr) 2005-11-10
HK1049011A1 (zh) 2003-04-25
WO2001023399A1 (en) 2001-04-05
EP1216257B1 (en) 2005-12-07
NO20021474D0 (no) 2002-03-25
AU778185B2 (en) 2004-11-18
PA8503301A1 (es) 2003-06-30
GEP20043241B (en) 2004-05-25
BG106636A (bg) 2003-01-31
CA2386079A1 (en) 2001-04-05
AR029887A1 (es) 2003-07-23
AP2002002458A0 (en) 2002-06-30
PE20010696A1 (es) 2001-07-05
UA73525C2 (en) 2005-08-15
CO5180581A1 (es) 2002-07-30
IL148222A0 (en) 2002-09-12
KR20020034206A (ko) 2002-05-08
MY133996A (en) 2007-11-30
SK4182002A3 (en) 2003-04-01
EP1216257A1 (en) 2002-06-26
EE200200172A (et) 2003-06-16
YU23102A (sh) 2006-01-16
JP2003510331A (ja) 2003-03-18
ZA200202461B (en) 2003-05-28
MA26822A1 (fr) 2004-12-20
ECSP003682A (es) 2002-04-23
GT200000161A (es) 2002-03-22
NO20021474L (no) 2002-05-22
CN1374967A (zh) 2002-10-16
KR100481605B1 (ko) 2005-04-08
MXPA02003308A (es) 2002-10-04
NZ517177A (en) 2003-10-31
CR6592A (es) 2004-02-23
HRP20020253A2 (en) 2004-04-30
EA005422B1 (ru) 2005-02-24
AU7035200A (en) 2001-04-30
HUP0202807A3 (en) 2005-02-28
PL357371A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0200782A (pt) Compostos para o tratamento da isquemia
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0014078A (pt) Inibidores de fator xa
PT956858E (pt) Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
BR0110420A (pt) Agonistas muscarìnicos
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
SE0102315D0 (sv) Compounds
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR9811099A (pt) Inibidores de urocinase
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0001292A (pt) Desfolhante
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR0215336A (pt) Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
UY26514A1 (es) &#34; composición para el tratamiento de tejidos danados&#34;.
BR9909971A (pt) Uso de um composto, processo para tratamento ou prevenção da sìndrome de intestinos irritáveis, e, composição farmacêutica para o tratamento da sìndrome dos intestinos irritáveis
NO20020914D0 (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.